[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"brand-zhgshwuzhiyao":3},{"head":4,"company":28,"invest":30,"children":31,"shops":32,"category":33,"sameIndustry":5,"rid":6},{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"brandId":6,"brandLogo":7,"brandImage":5,"brandName":8,"webName":9,"balias":5,"enterId":10,"mainindustry":11,"industry":5,"brandType":5,"brandHonor":5,"brandTel":12,"establishdate":5,"brandBirth":13,"cityarea":5,"brandWebsite":5,"brandSobp":5,"brandVisit":5,"totalVisits":14,"status":15,"isDeleted":15,"comment":5,"remark":5,"logoExistStatus":16,"imageExistStatus":16,"industryId":5,"industryRanking":5,"score":5,"enterName":17,"mallShopList":18,"brandSummary":19,"likes":5,"unlikes":5,"follow":5,"pagetitle":20,"pagekeywords":21,"pagedesc":22,"brandContent":23,"province":5,"city":5,"area":5,"detailaddress":24,"unifiedscc":5,"enterType":5,"enterLegalperson":5,"enterStablishdate":25,"regauthority":5,"licenseValidity":26,"approvaldate":25,"regcapital":5,"incapital":5,"businessscope":5,"ownBrand":5,"enterTelphone":5,"enterWebsite":27,"business":5,"enterQq":5,"enterMail":5,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"regtrademark":5},null,"41957","\u002Fprofile\u002Fupload\u002F2023\u002F12\u002F02\u002F0cd1352f7540e5d952b997e9152b5d93.gif","中国生物制药","zhgshwuzhiyao",35551,10006,"010-59257300","北京市",623,0,"1","中国生物制药有限公司",[],"中国生物制药是一家在港交所上市的创新研究和研发驱动型医药公司（股票代码：01177），主要透过应用先进的生物技术和中药现代化技术，研发、生产及销售多种促进人类健康的化学药品、生物药品及中药现代制剂，产品以生物药和化学药为主，主要覆盖肿瘤、肝病、呼吸系统、外科\u002F镇痛四大治疗领域。","中国生物制药品牌简介_中国生物药业怎么样→品牌之家","中国生物制药,中国生物制药肝药,中国生物制药肺癌药,中国生物制药肿瘤药,中国生物制药正大天晴","中国生物药业品牌简介，品牌之家为您推荐中国生物制药品牌历程、产品价格、口碑评价等内容。","中国生物制药公司是一家综合性兼集团化制药企业，公司主要透过应用先进的生物技术和中药现代化技术，研发、生产及销售多种促进人类健康的化学药品、生物药品及中药现代制剂\n\n中国生物制药有限公司及附属公司是领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智能化生产和强大销售体系全产业链。产品包括多种生物药和化学药，在肿瘤、肝病、心脑血管病、骨科、消化系统、抗感染及呼吸系统疾病等多个极具潜力的治疗领域处于优势地位。\n\n公司于2000年在香港联交所上市，2013年入选MSCI全球标准指数之中国指数成分股；2018年入选恒生指数成分股；2019年入选恒生中国企业指数成分股；2020年入选恒生沪深港通生物科技50指数成分股、恒生中国（香港上市）25指数。\n\n公司持续取得卓越成就和稳健发展，与高度重视研发及创新密不可分：坚持研发投入和产品创新能力行业领先；立足政策趋势，围绕主营业务的关联拓展，全面布局大健康发展战略；积极利用大数据、人工智能及科技金融等新技术和手段，不断提升企业的管理和研发、生产和行销效率。\n\n中国生物制药将继承正大集团“利国、利民、利企业”的价值观、秉承“健康、快乐、长寿”的使命，立足自主创新，引进全球创新技术，巩固在中国市场的领先地位。望与有识之士共享医药健康产业的发展成果，鼎力合作、共赢未来！","香港香港湾仔港湾道1号会展中心办公大楼41楼09室","1999-12-31","-","www.sinobiopharm.com\u002F",{"enterId":29,"enterName":17,"province":5,"city":5,"area":5,"detailaddress":24,"unifiedscc":5,"enterType":5,"enterLegalperson":5,"enterStablishdate":25,"regauthority":5,"licenseValidity":26,"approvaldate":25,"regcapital":5,"incapital":5,"businessscope":5,"ownBrand":5,"enterTelphone":5,"enterWebsite":27,"business":5,"performance":5,"socialSecurity":5,"registrationNumber":5,"enterQq":5,"enterMail":5,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"status":15,"regtrademark":5,"remark":5},"35551",{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"id":5,"brandId":5,"brandName":5,"busmodel":5,"franchiseFund":5,"totalStores":5,"devmodel":5,"franchiseIndustry":5,"investmenttel":5,"suitablePeople":5,"state":5},[],[],[34],{"createTime":35,"updateTime":36,"createBy":5,"updateBy":5,"industryId":37,"webId":5,"industryName":38,"industryAlias":5,"industryIcon":5,"industryTrans":39,"pageTitle":40,"pageDesc":41,"pageKeywords":42,"mainTitle":43,"pageSubtitle":44,"indSummary":45,"industryLevel":46,"parentId":47,"parentName":5,"sortOrder":48,"status":15,"classifyVisit":5,"totalVisits":49,"searchName":5,"starLevel":5,"limit":5},"2000-01-01 00:00:00","2026-06-16 16:50:00","10006","生物科技","\u002Fprofile\u002Fupload\u002F2023\u002F11\u002F08\u002F19f46e89d8cd077b73c7adb33bb2b59f.png","生物科技公司十大排行榜-国内知名生物科技公司有哪些-ZGALL品牌榜","2026年十大生物科技公司排行榜最新发布，生物科技公司十大排行榜前十名有中国生物、中国生物制药、百济神州、恒瑞、豪森药业、百利天恒、康方、复星医药、石药、信达。生物科技十大品牌排行榜由品牌研究部门收集整理大数据分析研究得出，帮助你了解中国生物科技公司有哪些。","生物科技公司排名前十有哪些,中国生物科技公司排名前十,生物科技有限公司排名,中国生物科技公司排名,全国生物科技公司排名","生物科技品牌排行榜","2026生物科技公司，生物制药公司排行榜，国内生物医药科技公司有哪些","生物科技哪个好？品牌TOP榜权威发布2026年生物科技名录；居前十的有：中国生物CNBG、中国生物制药、百济神州BeiGene、恒瑞医药、豪森药业、百利天恒、康方Akesobio、复星医药、石药CSPC、信达生物Innovent等，【行业品牌名录】基于大数据与人工智能技术，整合300+国际权威榜单及企业申报数据，通过算法分析市场占有率、创新力等12项指标，并解析超百万条舆情信息，采用加权模型（算法60%+专家30%+用户10%）生成动态排名。数据月度更新，申报需通过ISO认证审核，排名不分先后，仅供参考。",3,1411,99,589]